Screening for liver disease is an integral component of metabolic care

May 10, 2024

10 min watch

We were unable to process your request. Please try again later. If you continue to have this issue please contact

NEW ORLEANS — In this video exclusive, Jonathan D. Leffert, MD, talks with Scott D. Isaacs, MD, FACP, FACE, and Sangeeta Kashyap, MD, about nomenclature for liver disease and how endocrinologists should approach screening and treatment.

Leffert is managing partner at North Texas Endocrine Center, a past president of the American Association of Clinical Endocrinology and a Healio | Endocrine Today Editorial Board Member. Isaacs is adjunct associate professor of medicine at Emory University School of Medicine and president-elect of AACE. Kashyap is assistant chief of clinical affairs in the division of endocrinology, diabetes and metabolism at New York-Presbyterian/Weill Cornell Medical Center and a Healio | Endocrine Today Co-editor.

Isaacs explains the reasons behind the name change, recently adopted by several organizations, from “non-alcoholic fatty liver disease” to “metabolic dysfunction-associated steatotic liver disease” or MASLD.

Isaacs and Kashyap describe steps for diagnosing MASLD, strategies for weight loss and management of metabolic comorbidities, and medications to treat steatosis.

“[Screening for MASLD] is part and parcel in diabetes care now,” Kashyap said. “Even if they’re not diabetic, if they’re prediabetic, if they’re overweight with metabolic syndrome, every patient needs to have this done.”

We will be happy to hear your thoughts

Leave a reply

Belli Health
Shopping cart